Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CYCLON HIT

Financiado

Cerrado

NANOCARRIERS FOR THE DELIVERY OF ANTIMICROBIAL AGENTS TO FIGHT RESISTANCE MECHAN...

NANOCARRIERS FOR THE DELIVERY OF ANTIMICROBIAL AGENTS TO FIGHT RESISTANCE MECHANISMS The worldwide spread of antibiotic-resistant microorganisms can be viewed as an ecological consequence of the systematic use of antimicrobial agents. Resistant bacteria prevail in healthcare environments where antibiotic selective... ver más

28/02/2018

CNRS

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-02-28 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

CNRS

0.00€ | Lider

UGOT - GOETEBORGS UNIVERSITE...

N.D. | Participante

University of Iceland

N.D. | Participante

"NCSR ""D"""

N.D. | Participante

Proyectos interesantes

NANOTESTS

Nanotechnology

Medical Technol...

224K€ Cerrado

PID2020-114347RB-C31

Nanotechnology

Medical Technol...

133K€ Cerrado

NAREB

Nanotechnology

Medical Technol...

13M€ Cerrado

NANOCÁPSULAS POLIMÉRICAS BIODEGRADABLES E INT...

Nanotechnology

Medical Technol...

554K€ Cerrado

PID2020-113081RB-I00

Nanotechnology

Medical Technol...

169K€ Cerrado

NANOZID

Nanotechnology

Medical Technol...

214K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The worldwide spread of antibiotic-resistant microorganisms can be viewed as an ecological consequence of the systematic use of antimicrobial agents. Resistant bacteria prevail in healthcare environments where antibiotic selective pressure is intensive. Novel therapeutic approaches are urgently required to deliver the well-documented existing drugs in an optimized fashion to: i) protect them toward degradation; ii) increase their bioavailability; iii) reduce toxic side effects; iv) increase patient compliance and iv) reduce treatment duration and related costs. In this sense, nanocarriers based on cyclodextrins (CDs) are particularly appealing for the delivery of antibiotics. This approach is of main interest for tuberculosis (TB), infections related to Salmonella Typhimurium, Staphyloccocus aureus and for species most frequently implicated in hospital infections such as enteric gram-negative rods. We will design and characterize CD-based nanocarriers, test their ability to encapsulate drugs, study their efficacy in vitro on bacteria and infected cells. The best formulation will be tested in vivo and scaled up. The objectives of the CycloN Hit project are to take full advantage of nanotechnology and of the high level interdisciplinary expertise of the partners to efficiently encapsulate and protect antibiotics in nanocarriers to combat resistant bacteria, and study the mechanisms in biological systems using state-of-the art techniques. This will be accomplished through a strong and demanding training program for 11 Early Stage and 5 young Experienced Researchers which will gather interdisciplinary expertise of 11 Full partners and 6 Associated partners, of which 7 are SMEs. Using the most recent advances in the nanomedicine field, the final goal of the CycloN Hit project is to bring to the preclinical studies an antibiotic formulation for the treatment of TB and more tailored alternative therapeutic approaches for other resistant microorganisms.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores